alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–20 of 20 studies with an author at Tongji Hospital (CN) · 27,780 in the whole library · How the 0–100 score works

Download bibliography of these 20 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 13,259 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Blood pressure reduction and all-cause dementia in people with uncontrolled hypertension: an open-label, blinded-endpoint, cluster-randomized trial

✓ Peer-reviewed alzhub usefulness score 82 out of 100. Nature Medicine 2025-04-21

Dementia is a leading cause of death and disability worldwide. 3 key findings →

Design: RCT Participants: 33,995 Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Annals of neurology 2011-03-11

There is a clear need to develop biomarkers for Parkinson disease (PD) diagnosis, differential diagnosis of Parkinsonian disorders, and monitoring disease progression. 4 key findings →

Design: cross-sectional Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Active Travel Mode and Incident Dementia and Brain Structure

✓ Peer-reviewed alzhub usefulness score 57 out of 100. JAMA Network Open 2025-06-09

The study encompassed 479 723 participants (mean [SD] age, 56.5 [8.1] years; 260 730 females [54.4%]), including 271 690 in the YOD analyses and 334 939 in the LOD analyses. 5 key findings →

Design: cohort study Participants: 723 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

TREM2 variants and risk of Alzheimer's disease: a meta-analysis

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2015-06-03

Recent studies show that heterozygous variant of triggering receptor expressed on myeloid cells 2 (TREM2) increase the risk of Alzheimer's disease (AD) but with inconclusive results. 3 key findings →

Design: meta-analysis Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

HMOX1-LDHB interaction promotes ferroptosis by inducing mitochondrial dysfunction in foamy macrophages during advanced atherosclerosis

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Developmental cell 2024-12-27

Advanced atherosclerosis is the pathological basis for acute cardiovascular events, with significant residual risk of recurrent clinical events despite contemporary treatment. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Pain, agitation, and delirium practices in Chinese intensive care units: A national multicenter survey study

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Chinese Medical Journal 2025-10-24

To the Editor: The standardized management of pain–agitation–delirium (PAD) represents a fundamental component of clinical practice in intensive care units (ICUs).[1] Evidence-based analgesia and sedation strategies not only alleviate patients’ physiological discomfort and psychological distress, but also significantly reduce mechanical ventilation duration, improve long-term prognosis, and optimize healthcare resource allocation.[1,2] Equally crucial is delirium management, as evidenced by studies demonstrating that delirium duration independently predicts mortality risk, hospital stay length, healthcare expenditures, and acquired dementia incidence.[3] Although existing studies have explored PAD management practices, most rely on clinicians’ subjective recall that may distort objective clinical realities and fail to reflect distinctive characteristics.[4] Therefore, this nationwide multicenter cross-sectional study, initiated by the Critical Care Analgesia and Sedation Quality Control Subspecialty Group under the China National Center for Medical Quality Control in Critical Care Medicine, aims to investigate the current status of PAD management in China. 5 key findings →

Design: cross-sectional Participants: 2,627 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Cognitive deficits and delayed neuronal loss in a mouse model of multiple microinfarcts

✓ Peer-reviewed alzhub usefulness score 47 out of 100. The Journal of neuroscience : the official journal of the Society for Neuroscience 2012-12-01

Microinfarcts are a common clinical feature of the aging brain, particularly in patients with cognitive decline or vascular or Alzheimer's dementia. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The interaction between circadian syndrome and genetic susceptibility in the risk of incident dementia: A longitudinal cohort study

✓ Peer-reviewed alzhub usefulness score 44 out of 100. The Journal of Prevention of Alzheimer s Disease 2025-02-07

• CircS was associated with a 40.1 % increased risk of incident all-cause dementia. • A graded increase in dementia risk with escalating severity of CircS. • The presence of ≥ 3 CircS components was significantly associated with dementia. • There was a synergistic effect of CircS and high genetic risk on dementia. 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Predicting psychological distress in informal caregivers of older people with dementia: development and interpretation of a nomogram and XGBoost model

✓ Peer-reviewed alzhub usefulness score 43 out of 100. BMC Nursing 2025-10-22

The final models included six predictors: caregivers' social support, caregivers' employment situation, caregivers' average daily care duration, caregivers' monthly family income, caregivers' self-efficacy and PwD's chronic disease. 5 key findings →

Design: cross-sectional Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Therapeutic Approaches and Potential Mechanisms of Small Extracellular Vesicles in Treating Vascular Dementia

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Cells 2025-03-11

Small extracellular vesicles (sEVs), including exosomes as a subtype, with a diameter typically less than 200 nm and originating from the endosomal system, are capable of transporting a diverse array of bioactive molecules, including proteins, nucleic acids, and lipids, thereby facilitating intercellular communication and modulating cellular functions. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces Alzheimer disease-associated tau hyperphosphorylation in the hippocampus of rats with type 2 diabetes

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2015-02-01

Impaired insulin signaling pathway in the brain in type 2 diabetes (T2D) is a risk factor for Alzheimer disease (AD). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

A mass-producible macaque model displays a durable Alzheimer-like cognitive deficit and hallmark amyloid-β/tau/neurofilament light chain pathologies

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of Alzheimer's disease : JAD 2025-04-23

BackgroundAlzheimer's disease (AD) is the most prevalent neurodegenerative disorder characterized by cognitive deficit and pathological accumulation of amyloid-β (Aβ) and tau proteins. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed